Biogen Inc. (BMV:BIIB)

Mexico flag Mexico · Delayed Price · Currency is MXN
2,550.00
0.00 (0.00%)
At close: Jun 3, 2025
-31.35%
Market Cap 372.21B
Revenue (ttm) 200.64B
Net Income (ttm) 30.24B
Shares Out n/a
EPS (ttm) 206.75
PE Ratio 12.31
Forward PE 8.45
Dividend n/a
Ex-Dividend Date n/a
Volume 26
Average Volume 150
Open 2,550.00
Previous Close n/a
Day's Range 2,550.00 - 2,550.00
52-Week Range 2,445.00 - 4,250.00
Beta 0.12
RSI 31.96
Earnings Date Jul 31, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]

Sector Healthcare
Founded 1978
Employees 7,605
Stock Exchange Mexican Stock Exchange
Ticker Symbol BIIB
Full Company Profile

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD Financial Statements

News

There is no news available yet.